Literature DB >> 7001976

Host defenses and immunologic alterations associated with chronic hemodialysis.

S E Goldblum, W P Reed.   

Abstract

Many of the complications experienced by patients undergoing hemodialysis can be attributed to their altered host defenses. Increased cutaneous staphylococcal carriage along with repeated intravascular cannulation and defective mucocutaneous barriers lead to frequent invasion by infectious agents. Pathogens encounter granulocytes with subnormal locomotion, phagocytosis, and intracellular killing. Depressed cell-mediated immunity may be explained by shortened lymphocyte survival, lymphopenia, inhibition of lymphocyte transformation, and suppressor T-cell activity. This is manifested by cutaneous anergy, prolonged graft survival, altered tumor surveillance, and abnormal responses to hepatitis B and tuberculosis. Host interaction with the hemodialysis membrane leads to cellular disruption, which may induce autoantibodies. Activation of the alternate complement pathway during hemodialysis leads to granulocyte sequestration in small vessels, specifically within the lungs. These hemodialysis-induced alterations along with the manifestations of underlying chronic renal insufficiency may obscure clinical evaluation of these patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7001976     DOI: 10.7326/0003-4819-93-4-597

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  50 in total

1.  Outcomes of emergency surgery for acute abdomen in dialysis patients: experience of a single community hospital.

Authors:  Takahiro Tomino; Hideaki Uchiyama; Shinji Itoh; Takahiro Higashi; Ai Edagawa; Akinori Egashira; Daihiko Eguchi; Hirofumi Kawanaka; Toshiroh Okuyama; Masahiro Tateishi; Daisuke Korenaga; Kenji Takenaka
Journal:  Surg Today       Date:  2013-07-25       Impact factor: 2.549

2.  Expanded CD14+ CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis.

Authors:  W A Nockher; J E Scherberich
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

3.  Bladder cancer in a patient on long-term haemodialysis.

Authors:  H Hadatsuki; I Sasagawa; H Suzuki; H Yaguchi; A Mutoh; Y Kubota; T Nakada
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

4.  Hepatitis C Virus Infection in Haemodialysis Patients: "Wolf in Sheep's Clothing".

Authors:  G S Chopra; R M Gupta; S R Gedela; P P Varma; R Rai; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-05-30

5.  Hepatitis B vaccination and immune response in children with malignant diseases.

Authors:  U Entacher; O Jürgenssen; L Thun-Hohenstein; G Simbruner; A Khoss; H Wank; G Neuwirth; H Gadner; W Frisch-Niggemeyer
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

6.  Two cases of urogenital malignancies in male patients undergoing maintenance haemodialysis.

Authors:  Y Makita; T Iwamoto; K Sagiyama; A Nagaoka; M Kinjo; M Noguchi; K Aramaki; S Okuda; M Fujishima
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

7.  Blood transfusion suppresses cutaneous cell-mediated immunity.

Authors:  J D Schot; R K Schuurman
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

8.  Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods.

Authors:  P M Schneeberger; I Keur; W van der Vliet; K van Hoek; H Boswijk; A M van Loon; W C van Dijk; R H Kauffmann; W Quint; L J van Doorn
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

Review 9.  Recovery of uncommon bacteria from blood: association with neoplastic disease.

Authors:  J L Beebe; E W Koneman
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

10.  The seroprevalence of human papillomavirus by immune status and by ethnicity in London.

Authors:  Delphine Casabonne; Tim Waterboer; Kristina M Michael; Michael Pawlita; Liza Mitchell; Robert Newton; Catherine Harwood; Charlotte Proby
Journal:  Infect Agent Cancer       Date:  2009-09-14       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.